• 1
    Kanzler H, Kuppers R, Hansmann ML, Rajewsky K. Hodgkin and Reed- Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. J Exp Med 1996; 184: 1495505.
  • 2
    Harris NL. Hodgkin's disease: classification and differential diagnosis. Mod Pathol 1999; 12: 15975.
  • 3
    Boyle MJ, Vasak E, Tschuchnigg M, Turner JJ, Sculley T, Penny R, Cooper DA, Tindall B, Sewell WA. Subtypes of Epstein-Barr virus (EBV) in Hodgkin's disease: association between B-type EBV and immunocompromise. Blood 1993; 81: 46874.
  • 4
    Roth J, Daus H, Gause A, Trumper L, Pfreundschuh M. Detection of Epstein-Barr virus DNA in Hodgkin- and Reed-Sternberg-cells by single cell PCR. Leuk Lymphoma 1994; 13: 13742.
  • 5
    Martin JM, Warnke RA. A quantitative comparison of T-cell subsets in Hodgkin's disease and reactive hyperplasia. Frozen section immunohistochemistry. Cancer 1984;53: 24505.
  • 6
    Mourad WA, Alsohaibani MO, Saddik M, Bazerbashi S. Epstein-Barr virus expression in Hodgkin's disease: Correlation with histologic subtype and T and B lymphocyte distribution. Ann Saud Med 1998; 18: 296300.
  • 7
    Forni M, Hofman FM, Parker JW, Lukes RJ, Taylor CR. B- and T-lymphocytes in Hodgkin's disease. An immunohistochemical study utilizing heterologous and monoclonal antibodies. Cancer 1985;55: 72837.
  • 8
    Hess JL, Bodis S, Pinkus G, Silver B, Mauch P. Histopathologic grading of nodular sclerosis Hodgkin's disease. Lack of prognostic significance in 254 surgically staged patients. Cancer 1994;74: 70814.
  • 9
    Ferry JA, Linggood RM, Convery KM, Efird JT, Eliseo R, Harris NL. Hodgkin disease, nodular sclerosis type. Implications of histologic subclassification Cancer 1993; 71: 45763.
  • 10
    MacLennan KA, Bennett MH, Tu A, Hudson BV, Easterling MJ, Hudson GV, Jelliffe AM. Relationship of histopathologic features to survival and relapse in nodular sclerosing Hodgkin's disease. A study of 1659 patients. Cancer 1989;64: 168693.
  • 11
    Van Spronsen DJ, Vrints LW, Hofstra G, Grommelin MA, Coebergh JW, Breed WP. Disappearance of prognostic significance of histopathological grading of nodular sclerosis Hodgkin's disease for unselected patients. Br J Haematol 1997; 96: 3227.
  • 12
    Christiansen MS, Mourad WA, Hales ML, Oldring DJ. Spindle cell malignant lymphoepithelial lesion of the parotid gland: Clinical, light microscopic, ultrastructural, and in situ hybridization findings in one case. Mod Pathol 1995; 8: 7115.
  • 13
    Khan G, Coates PJ, Gupta RK, Kangro HO, Slavin G. Presence of Epstein-Barr virus in Hodgkin's disease is not exclusive to Reed-Sternberg cells. Am J Pathol 1992; 140: 75762.
  • 14
    Clerici M, Ferrario E, Trabattoni D, Viviani S, Bonfanti V, Venzon DJ, Clerici E, Shearer GM, Villa ML. Multiple defects of T helper cell function in newly diagnosed patients with Hodgkin's disease. Eur J Cancer 1994; 30A: 146470.
  • 15
    De Angelis P, Kimmel M, Lacher M, Filippa D, Melamed MR. T-cell subsets in peripheral blood of patients with newly diagnosed and posttreatment Hodgkin's and non-Hodgkin's lymphomas. Analysis by monoclonal antibody staining and flow cytometry. Anal Quant Cytol Histol 1988;10: 23542.
  • 16
    Lauria F, Raspadori D, Foa R, Tazzari PL, Lusso P, Fierro MT, Matera L, Baccarani M, Tura S. Normal T-lymphocyte function in patients with Hodgkin's disease in long lasting remission. Tumori 1986; 72: 7580.
  • 17
    Frisan T, Sjoberg J, Dolcetti R, Boiocchi M, De Re V, Carbone A, et al. Local suppression of Epstein-Barr virus (EBV)-specific cytotoxicity in biopsies of EBV-positive Hodgkin's disease. Blood 1995; 86: 1493501.
  • 18
    Lauria F, Foa R, Gobbi M, Camaschella C, Lusso P, Raspadori D, Tura S. Increased proportion of suppressor/cytotoxic (OKT8+) cells in patients with Hodgkin's disease in long-lasting remission. Cancer 1983; 52: 13858.
  • 19
    Moran CA, Tuur S, Angritt P, Reid AH, O'Leary TJ. Epstein-Barr virus in Hodgkin's disease from patients with human immunodeficiency virus infection. Mod Pathol 1992; 5: 858.
  • 20
    Rodriguez JN, Aguayo DM, Martin I, Dieguez JC, Pardos D, Pujol E. Hodgkin's disease and HIV: relations between CD4/CD8 rate, histology and stage. Rev Clin Esp 1994; 194: 5436.
  • 21
    Tinguely M, Vonlanthen R, Muller E, Dommann-Scherrer CC, Schneider J, Laissue JA, Borisch B. Hodgkin's disease-like lymphoproliferative disorders in patients with different underlying immunodeficiency states. Mod Pathol 1998; 11: 30712.
  • 22
    Knowles DM. Immunodeficiency-associated lymphoproliferative disorders. Mod Pathol 1999; 12: 20017.
  • 23
    Levy R, Colonna P, Tourani JM, Gastaut JA, Brice P, Raphael M, Taillan B, Andrieu JM. Human immunodeficiency virus associated Hodgkin's disease: Report of 45 cases from the French Registry of HIV-Associated Tumors. Leuk Lymphoma 1995; 16: 4516.
  • 24
    Reynolds DJ, Banks PM, Gulley ML. New characterization of infectious mononucleosis and phenotypic comparison with Hodgkin's disease. Am J Pathol 1995; 146: 37988
  • 25
    Segal GH, Kjeldsberg CR, Smith GP, Perkins SL. CD30 antigen expression in florid immunoblastic proliferations. A clinicopathologic study of 14 cases. Am J Clin Pathol 1994;102: 2928.
  • 26
    Kamel OW, Weiss LM, van de Rijn M, Colby TV, Kingma DW, Jaffe ES. Hodgkin's disease and lymphoproliferations resembling Hodgkin's disease in patients receiving long-term low-dose methotrexate therapy. Am J Surg Pathol 1996; 20: 127987.
  • 27
    Elenitoba-Johnson KS, Jaffe ES. Lymphoproliferative disorders associated with congenital immunodeficiencies. Semin Diagn Pathol 1997; 14: 3547.
  • 28
    Rosenberg SA. The management of Hodgkin's disease: half a century of change. The Kaplan Memorial Lecture. Ann Oncol 1996;7: 55560.
  • 29
    Wirth A, Chao M, Corry J, Laidlaw C, Yuen K, Ryan G, Byram D, Davis S, Kiffer J, Quong G, Liew K. Mantle irradiation alone for clinical stage I-II Hodgkin's disease: long-term follow-up and analysis of prognostic factors in 261 patients. J Clin Oncol 1999; 17: 23040.
  • 30
    Healy EA, Tarbell NJ, Kalish LA, Silver B, Rosenthal DS, Marcus K, Shulman LN, Coleman CN, Canellos G, Weinstein H, Mauch P. Prognostic factors for patients with Hodgkin disease in first relapse. Cancer 1993; 71: 261320.
  • 31
    Mendenhall NP, Cantor AB, Barre DM, Lynch JW, Million RR. The role of prognostic factors in treatment selection for early-stage Hodgkin's disease. Am J Clin Oncol 1994; 17: 18995.
  • 32
    Murray PG, Billingham LJ, Hassan HT, Flavell JR, Nelson PN, Scott K, Reynolds G, Constandinou CM, Kerr DJ, Devey EC, Crocker J, Young LS. Effect of Epstein-Barr virus infection on response to chemotherapy and survival in Hodgkin's disease. Blood 1999; 94: 4427.
  • 33
    Freeman J, Kellock DB, Yu CC, Crocker J, Levison DA, Hall PA. Proliferating cell nuclear antigen (PCNA) and nucleolar organiser regions in Hodgkin's disease: correlation with morphology. J Clin Pathol 1993; 46: 4469.
  • 34
    Naresh KN, Johnson J, Srinivas V, Soman CS, Saikia T, Advani SH, Badwe RA, Dinshaw KA, Muckaden M, Magrath I, Bhatia K. Epstein-Barr virus association in classical Hodgkin's disease provides survival advantage to patients and correlates with higher expression of proliferation markers in Reed-Sternberg cells. Ann Oncol 2000;>11(1): 916.
  • 35
    Oudejans JJ, Jiwa MM, Meijer CJ. Epstein-Barr virus in Hodgkin's disease: more than just an innocent bystander. J Pathol 1997; 181: 3536.